Source:Cancer Epidemiology, Volume 50, Part A
Author(s): Tohru Morisada, Katsuhiro Teramoto, Hirokuni Takano, Ikuko Sakamoto, Hiroshi Nishio, Takashi Iwata, Akihiko Hashi, Ryohei Katoh, Aikou Okamoto, Hiroshi Sasaki, Eiji Nakatani, Satoshi Teramukai, Daisuke Aoki
BackgroundTo assess the efficacy of screening with concurrent liquid-based cytology and human papillomavirus (HPV) testing for primary cervical cancer screening, we initiated a randomized trial entitled CervIcal cancer screening Trial by Randomization of HPV testing intervention for Upcoming Screening (CITRUS).MethodsBetween June 2013 and March 2015, women aged 30–64 years of age who participated in a regular cervical cancer screening program (every 2 years) were invited to enrollment of our study. After giving their informed consent, 18,402 women were randomly assigned to liquid-based cytology as the control group (n=9145) or to HPV DNA testing with liquid-based cytology as the intervention group (n=9257). We subsequently compared the incidence rate of cervical intraepithelial neoplasia (CIN), the rate of false positive tests and the rate of overdiagnosis, as well as assessing the risks and benefits of receiving screening for women in both groups. The primary outcome of our study was the incidence of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) during the study period of around 6 years.ResultsIn the control group, 97.9% of women were NILM, and 2.06% ASC-US or worse (ASC-US+). In the intervention group, 87.13% of women were NILM/HPV negative, 0.72% ASC-US/HPV negative, 10.34% NILM/HPV positive, 0.69% ASC-US/HPV positive, 0.90% worse than ASC-US/either HPV. Positive HPV testing was not linearly related to age in our study.ConclusionsInsights from CITRUS will provide future prospects for cervical cancer screening focused on the use of HPV testing in Japan.Clinical trial registration number: NCT01895517, UMIN000010843, TRIUC1312.
http://ift.tt/2w4L6k3
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου